Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
316.5 SEK | -1.40% | -2.16% | -3.95% |
Sales 2024 * | 794M 72.75M | Sales 2025 * | 1.07B 98.46M | Capitalization | 9.97B 913M |
---|---|---|---|---|---|
Net income 2024 * | 70M 6.41M | Net income 2025 * | 158M 14.47M | EV / Sales 2024 * | 12 x |
Net cash position 2024 * | 454M 41.55M | Net cash position 2025 * | 476M 43.61M | EV / Sales 2025 * | 8.83 x |
P/E ratio 2024 * |
152
x | P/E ratio 2025 * |
66.3
x | Employees | 160 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.13% |
Latest transcript on Xvivo Perfusion AB
1 day | -1.40% | ||
1 week | -2.16% | ||
Current month | +15.09% | ||
1 month | +17.22% | ||
3 months | -0.47% | ||
6 months | +41.61% | ||
Current year | -3.95% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 12-08-31 | |
Director of Finance/CFO | 39 | - | |
Chief Tech/Sci/R&D Officer | 57 | 20-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Camilla Öberg
BRD | Director/Board Member | 60 | 16-04-30 |
Chairman | 65 | - | |
Lars Henrikson
BRD | Director/Board Member | 69 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 316.5 | -1.40% | 27,963 |
24-04-18 | 321 | -2.13% | 41,987 |
24-04-17 | 328 | +1.08% | 28,621 |
24-04-16 | 324.5 | -2.26% | 99,215 |
24-04-15 | 332 | +2.63% | 75,889 |
Delayed Quote Nasdaq Stockholm, April 19, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.95% | 914M | |
-2.53% | 186B | |
-3.52% | 106B | |
+5.33% | 50.39B | |
+16.43% | 47.65B | |
-1.73% | 39.29B | |
+5.66% | 27.24B | |
-2.01% | 25.42B | |
+9.84% | 24.39B | |
-1.87% | 24.54B |
- Stock Market
- Equities
- XVIVO Stock